CLRB
Income statement / Annual
Last year (2023), Cellectar Biosciences, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Cellectar Biosciences, Inc.'s net income was -$37.98 M.
See Cellectar Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$192,375.00
|
$238,867.00
|
$227,636.00
|
$207,929.00
|
$189,360.00
|
$82,265.00
|
$1.55 M
|
$356,665.00
|
$362,502.00
|
$0.00
|
| Gross Profit |
-$192,375.00
|
-$238,867.00
|
-$227,636.00
|
-$207,929.00
|
-$189,360.00
|
-$82,265.00
|
-$1.55 M
|
-$356,665.00
|
-$362,502.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$27.27 M
|
$19.22 M
|
$17.59 M
|
$10.14 M
|
$9.00 M
|
$6.84 M
|
$9.47 M
|
$4.75 M
|
$5.16 M
|
$5.96 M
|
| General & Administrative Expenses |
$10.75 M
|
$9.59 M
|
$6.54 M
|
$5.15 M
|
$5.18 M
|
$4.82 M
|
$4.14 M
|
$4.70 M
|
$3.40 M
|
$3.70 M
|
| Selling & Marketing Expenses |
$945,184.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.69 M
|
$9.59 M
|
$6.54 M
|
$5.15 M
|
$5.18 M
|
$4.82 M
|
$4.14 M
|
$4.70 M
|
$3.40 M
|
$3.70 M
|
| Other Expenses |
-$0.00
|
$0.00
|
$6,634.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$38.96 M
|
$28.81 M
|
$24.13 M
|
$15.29 M
|
$14.18 M
|
$11.66 M
|
$13.60 M
|
$9.45 M
|
$8.55 M
|
$9.67 M
|
| Cost And Expenses |
$38.96 M
|
$28.81 M
|
$24.13 M
|
$15.29 M
|
$14.18 M
|
$11.66 M
|
$13.60 M
|
$9.45 M
|
$8.55 M
|
$9.67 M
|
| Interest Income |
$0.00
|
$152,519.00
|
$2,284.00
|
$10,897.00
|
$42,712.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$29,687.00
|
$16,605.00
|
$7,897.00
|
$841.00
|
$446,314.00
|
| Depreciation & Amortization |
$192,375.00
|
$238,867.00
|
$227,636.00
|
$207,929.00
|
$189,360.00
|
$82,265.00
|
$1.55 M
|
$356,665.00
|
$362,502.00
|
$367,197.00
|
| EBITDA |
-$38.77 M |
-$28.67 M |
-$23.98 M |
-$15.15 M |
-$13.90 M |
-$13.16 M |
-$12.05 M |
-$9.09 M |
-$8.19 M |
-$9.30 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$917,147.00
|
$152,519.00
|
$8,918.00
|
$196,177.00
|
$85,712.00
|
$91,737.00
|
$38,680.00
|
$3.27 M
|
$3.26 M
|
$1.78 M
|
| Income Before Tax |
-$38.04 M
|
-$28.66 M
|
-$24.12 M
|
-$15.09 M
|
-$14.09 M
|
-$13.24 M
|
-$13.56 M
|
-$6.18 M
|
-$5.50 M
|
-$8.11 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$60,000.00
|
-$60,000.00
|
-$152,199.00
|
-$337,630.00
|
-$218,510.00
|
-$1.55 M
|
-$38,680.00
|
-$3.27 M
|
-$3.42 M
|
-$1.56 M
|
| Net Income |
-$37.98 M
|
-$28.60 M
|
-$23.97 M
|
-$14.76 M
|
-$13.87 M
|
-$13.24 M
|
-$13.56 M
|
-$6.18 M
|
-$5.50 M
|
-$8.11 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.11 |
-4.05 |
-4.32 |
-7.45 |
-18.08 |
-44.7 |
-96.66 |
-141.54 |
-702.78 |
-1765.33 |
| EPS Diluted |
-3.11 |
-4.05 |
-4.32 |
-7.45 |
-18.08 |
-44.7 |
-96.66 |
-141.54 |
-702.78 |
-1765.33 |
| Weighted Average Shares Out |
$12.22 M
|
$7.06 M
|
$5.55 M
|
$1.98 M
|
$767,509.00
|
$296,197.00
|
$140,313.00
|
$43,666.00
|
$7,819.00
|
$4,592.00
|
| Weighted Average Shares Out Diluted |
$12.22 M
|
$7.06 M
|
$5.55 M
|
$1.98 M
|
$767,509.00
|
$296,197.00
|
$140,313.00
|
$43,666.00
|
$7,819.00
|
$4,592.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
